avatrombopag

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
024620142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Avatrombopag, an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist, is currently in clinical… (More)
Is this relevant?
2018
2018
BACKGROUND & AIMS Patients with thrombocytopenia and chronic liver disease (CLD) may require platelet transfusions before… (More)
  • figure 3
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2018
2018
AIMS Avatrombopag, a thrombopoietin receptor agonist, is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A. We assessed three… (More)
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2018
2018
Avatrombopag (Doptelet®) is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by… (More)
Is this relevant?
2018
2018
Avatrombopag, a c-Mpl agonist, has been developed to provide an alternative therapy to standard platelet transfusion care for the… (More)
Is this relevant?
Review
2016
Review
2016
Patients with chronic liver diseases (CLD) undergo a range of invasive procedures during their clinical lifetime. Various… (More)
Is this relevant?
Review
2015
Review
2015
Thrombocytopenia (platelet count <150 × 109/L) often complicates chronic liver disease, impeding optimal management of these… (More)
  • figure 1
Is this relevant?
2014
2014
Stimulation of platelet production by thrombopoietin-receptor agonists (TPO-RAs) is an effective second-line treatment in immune… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
BACKGROUND & AIMS This is a phase II multicentre study to investigate the efficacy and safety of avatrombopag (E5501), an… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?